CDK1 and B-cell chronic lymphocytic leukemia: Dinaciclib is a more selective CDK inhibitor of CDK1, CDK2, CDK5, and CDK9 with IC50 of <5nM in an in vitro kinase assay and currently under development of phase III clinical trial in CLL.